When a @entity548 complication occurs during therapy with heparin or @entity2067 antagonists, there is an option to give a specific antidote. Several new anticoagulants have been developed that are likely to have some risk of @entity548 complications, for which no specific antidotes are available. Interestingly, it is unknown how often the use of an antidote is necessary in clinical practice. We investigated 1877 @entity1 treated for @entity1211 included in three large clinical trials, of which 181 (9.6%) had a total of 225 adjudicated @entity548 episodes; 46 @entity548 being designated as major. Some form of antidote was given to 26 (14.4%) @entity1 with a @entity548 . Of the @entity1 with at least one major @entity548 , 19 (41.3%) received an antidote. @entity2067 was given to 23 (1.2%) @entity1 , one (0.05%) @entity1 received protamin sulfate and seven (0.4%) @entity1 received fresh frozen plasma. The use of antidotes was comparable for initial and long-term treatment. Antidotes were statistically significantly more frequently given in Canada as compared to other participating countries. @entity2067 was more frequently given in case of a higher international normalized ratio value. Although antidotes against anticoagulant treatment are widely available, our analysis shows that in only a very small number of @entity1 a direct, or slow-acting antidote to reverse the anticoagulant effect was used.

The use of specific antidotes as a response to XXXX complications during anticoagulant therapy for @entity1211 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhages', 'hemorrhage', 'bleeding'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['Vitamin K', 'vitamin K']
@entity548 :: (MESH:D006470,Disease) :: ['bleeding']
